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Abstract
Background: Cytokines as molecular adjuvant play a critical role in differentiation of effector T cell subsets and in
determination of the magnitude of the response after vaccination. In this study, we investigated the effects of
GM-CSF and IL-2 as adjuvant on the immune responses of VP1 recombinant protein as a model antigen for foot
and mouth disease.
Results: Six expression plasmids were constructed and expressed in E. coli BL21. In guinea pigs, the immunological
and molecular effects of the fusion proteins were determined by ELISA, LPA, DTH and semi-quantitative Reverse
Transcriptase PCR (RT-PCR). The data revealed that IL-2 and GM-CSF as adjuvant of VP1 could stimulate both
humoral and cell-mediated immune response. Interestingly, IL-2 and GM-CSF, either as a co-expressed protein or as
a mixture of two single proteins, showed much better adjuvant effects than that of single one.
Conclusions: IL-2 and GM-CSF could be used as a potential adjuvant for VP1 and had synergistic effect when
co-expressed or mixed with VP1.
Background
In recent years, there has been significant progress in
the development of candidate vaccines against foot and
mouth disease virus (FMDV), in the forms of both
whole virus and recombinant proteins. Practical applica-
tion of these vaccines, however, has often been limited
by the lack of suitable adjuvant capable of stimulating
an appropriate immune response in the absence of
adverse reactions.
Many compounds with adjuvant activity have been
identified, but none has been emerged as being univer-
sally superior [1,2]. Although adjuvant such as alum
adjuvant has been widely used with vaccines for many
years [3], alum does not effectively augment immune
response necessary for a number of new subunit protein
or peptide based vaccines [4]. There is a strong need for
alternative adjuvants that must not only enhance the
immune response but also drive it to achieve the appro-
priate type of protective immunity in each situation.
It is now evident that molecular adjuvant, especially
cytokines [5-7], could enhance and modulate the
immune responses induced by subunit vaccine. In many
studies cytokines were used to reinforce the ability of
the subunit vaccine to induce antigen-specific cellular
immune response against FMDV [8-11].
IL-2 is one of the most widely used adjuvants for vac-
cination to stimulate the proliferation and activation of
various immune effector cells such as T cells, NK cells,
B cells, and macrophages [12,13]. Granulocyte monocyte
colony stimulating factor (GM-CSF) is known to stimu-
late macrophage differentiation and proliferation, and to
activate antigen presenting cells [14]. IL-2 and GM-CSF
has been used as an effective adjuvant for DNA or pep-
tide based vaccines [15-17].
In this immunization study, we selected IL-2 and
GM-CSF as adjuvant for the VP1 subunit vaccine, with
an ultimate goal to verify whether these cytokines have
the ability to stimulate humoral immune response and
cellular immunity for FMDV.
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Construction of expression plasmids of BoIL-2,
BoGM-CSF and VP1
Bovine IL-2 (BoIL-2), Bovine GM-CSF (BoGM-CSF) and
VP1 gene were amplified and cloned into pGEX-6P-1
vector by using the restriction enzymes as described
before. Each construct was characterized by restriction
mapping with one vector band and specific target bands
at 405 bp, 450 bp, 378 bp and 669 bp, respectively,
followed by DNA sequencing. The results showed that
the plasmids of BoIL-2, BoGM-CSF and VP1 were cor-
rectly constructed with sequence integrity and right
orientation.
Construction of co-expression plasmids of BoIL-2,
BoGM-CSF and VP1
BoIL-2, BoGM-CSF and VP1 gene fragments were
amplified and cloned into pGEX-6P-1 vector by using
the restriction enzymes as described before. To
construct fused products of BoIL-2/BoGM-CSF/VP1,
BoIL-2/VP1, BoGM-CSF/VP1, These constructs were
characterized by double digestion with the correspond-
ing restriction enzymes and yielded fragments including
one vector band and specific target bands, of which 669
bp was expected for the VP1, 405 bp for the BoIL-2,
378 bp for the BoGM-CSF, 1089 bp for the BoIL-2/VP1,
1062 bp for the BoGM-CSF/VP1 and 1482 bp for the
BoIL-2/BoGM-CSF/VP1, respectively. It was further
confirmed by PCR with respective primers.
Characterization of the expressed proteins by SDS-PAGE
and Western blot analysis
To analyze the expressed products, 20 μl samples from
the supernatant and precipitation fractions of each cul-
ture were analyzed by SDS-PAGE. The result showed
that all products were GST fusion proteins and
expressed in inclusion body. 40 KDa, 51 KDa, 41 KDa,
65 KDa, 66 KDa, and 81 KDa were observed and
represented the sizes of BoGM-CSF, VP1, BoIL-2,
BoGM-CSF/VP1, BoIL-2/VP1, BoIL-2/BoGM-CSF/VP1,
respectively (Figure 1). The yield of expression for each
product is approximately 37% of the total cellular
proteins. These constructs were further confirmed by
Western-blots (Figure 2).
Dynamics of serum IgG of FMDV in the inoculated
guinea pigs
To evaluate the levels of total IgG against FMDV, the
sera obtained from immunized guinea pigs two week
after each injection were diluted 1:100 to perform
ELISA as shown in Figure 3. The IgG level of serum
samples of all groups was increased along with the
immunization time. Compared with the control group,
sera were detected positive in groups of BoIL-2/BoGM-
CSF/VP1, BoIL-2+BoGM-CSF/VP1 and negative in
others after the first immunization. After the second
and third immunizations, IgG levels were significant
higher and increased fast after the third injection in all
immunized groups.
Among the groups, IgG levels of BoIL-2/BoGM-CSF/
VP1 and BoIL-2/VP1+BoGM-CSF/VP1 groups were sta-
tistically significantly higher than those of other groups
(P < 0.05). The second high level of IgG was observed
Figure 1 SDS-PAGE analysis of recombinant protein expressed
in BL21.2 0μl precipitation was sampled from each cultural and
analyzed on 15% SDS-PAGE. The results showed that the expressed
products were respectively expressed in precipitation with specific
target bands of 40 KDa, 66 KDa, 81 KDa, 51 KDa, 41 KDa and 65
KDa, , which were well corresponded to the sizes of BoGM-CSF,
BoIL-2/VP1, BoIL-2/GM-CSF/VP, VP1, BoIL-2, BoGM-CSF/VP1. (Lane M:
Low molecular weight standard protein marker, Lane 1: BoGM-CSF,
Lane 2:BoIL-2/VP1, Lane 3: control, Lane 4: BoIL-2/GM-CSF/VP1, Lane
5: VP1, Lane 6: BoIL-2, Lane 7: BoGM-CSF/VP1).
Figure 2 Western blot analysis of recombinant protein
expressed in BL21. Recombinant proteins were purified and
analyzed by Western blot. In Western blot analysis, guinea pig anti-
BoIL-2 sera, guinea pig anti-BoGM-CSF sera and bovine FMDV
positive sera were respectively used as the primary antibodies, and
the expressions of recombinant proteins were all detected with one
specific target band, respectively. (Lane M: Low molecular weight
standard protein marker, Lane 1: BoGM-CSF, Lane 2:BoIL-2/VP1, Lane
3: control, Lane 4: BoIL-2/GM-CSF/VP1, Lane 5: VP1, Lane 6: BoIL-2,
Lane 7: BoGM-CSF/VP1).
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Figure 3 ELISA analysis of Sera IgG level. Sera IgG production profile after immunization antibody were analyzed as described in material and
methods. The IgG level was determined using ELISA and expressed as OD 450/OD 630. A: Sera IgG level after first immunization, B: Sera IgG level
after second immunization, C: Sera IgG level after third immunization.
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co-expressed or mixed with VP1 and group of vaccine
only induced slightly lower level of IgG than VP1+CFA
group, but not significantly different. The control groups
immunized with BoIL-2 or BoGM-CSF alone induced
the lowest level of IgG compared with PBS control
group.
Antigen specific T lymphocyte proliferation assays
To determine which cytokine induced better T cell
responses, single suspensions of lymphocytes were pre-
pared from guinea pig after the third immunization and
assayed with MTT method. As shown in Figure 4 com-
pared with the PBS control group, stimulation indexes
(SI) of all groups were increased significantly (P < 0.05).
Highest level of proliferation was observed in the group
inoculated with BoIL-2/BoGM-CSF/VP1 and followed
by the group of BoIL-2/VP1+BoGM-CSF/VP1. The next
level of proliferations were observed in four groups
given with single cytokine co-expressed or mixed with
VP1, followed by VP1 and vaccine groups, but there was
no statistically significance with the above four groups.
The result indicated that VP1 plus BoIL-2 and BoGM-
CSF could induce significant T cell response, and the
combined use of two cytokines had better effect than
that of single cytokine as adjuvant. It suggested that
these cytokines enhanced the cell-mediated immunity,
which was consistent with their known biological
function.
Antigen specific delayed-type hypersensitivity response
Delayed-type hypersensitivity (DTH) is a memory
immune response and directly reflects the cellular
immune response of body. All guinea pigs were trea-
ted as described before, and then the thicknesses of
footpad were measured respectively at 24 h, 48 h and
72 h. The effects of DTH were assessed by the thick-
ness of left footpad and right footpad ratio. As shown
in Figure 5 the highest level of DTH was observed in
the group of BoIL-2/BoGM-CSF/VP1, followed by
groups of VP1+CFA and BoIL-2/VP1+BoGM-CSF/
VP1. The middle level of DTH was seen in the groups
of vaccine and VP1, while the DTH level of the four
groups that the single cytokine co-expressed or mixed
with VP1 were slight lower than the former two
groups but no statistically significance. The back-
ground level of DTH was from groups of BoIL-2 and
BoGM-CSF.
Th1 and Th2 cytokine profile detected
by semi-quantitative RT-PCR
C y t o k i n e sp l a yad o m i n a n tr o l ei nm o d u l a t i n gi m m u n e
response against infection or in the effectiveness of vac-
cination. Therefore, semi-quantitative RT-PCR was used
to monitor the expression of the representative cyto-
kines. hypoxanthine phosphoribosyl transferase (HPRT),
a house-keeping gene, was used as a normalizing control
after guinea pigs were immunized. As shown in Figure 6
and Figure 7 the mRNAs of Th1 and Th2 types of
Figure 3    LAP analysis of T lymphocyte stimulation level 
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Figure 4 LAP analysis of T lymphocyte stimulation level. T lymphocyte proliferation in response to the inoculations with different proteins. T
lymphocytes were isolated from the Guinea pig (N = 7) and stimulated with 146 S antigen or unstimulated in vitro, and the stimulation index
was defined as the ratio of stimulated wells to unstimulated ones. T cell proliferation responses varied among all the groups.
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inoculated group. The groups of BoIL-2/BoGM-CSF/
VP1 and BoIL-2/VP1+BoGM-CSF/VP1 showed the
highest level of mRNAs of either Th1 or Th2 cytokines.
Expression of the cytokines in the groups with single
cytokine co-expressed or mixed with VP1 showed the
same level of either Th1 or Th2 cytokines as that of
groups of Vaccine and VP1. The results indicated that
BoIL-2 or BoGM-CSF co-immunized with VP1 could
induce both Th1 and Th2 immunity. For the side effects
of CFA, group of VP1+CFA showed a higher level of
mRNAs of Th2 cytokines than other groups except
groups of BoIL-2/BoGM-CSF/VP1 and BoIL-2/VP1
+BoGM-CSF/VP1. Groups of BoIL-2 and BoGM-CSF
induced the lowest level of cytokines expression.
Discussion
As an effective cell activator, complete freund’s adjuvant
could induce humoral immunity and cellular immunity
but were restricted to use by serious side effect. In this
regard, we examined the effects of cytokine as adjuvant
on promoting cellular or humoral immune response. In
this study, IL-2 and GM-CSF were selected as adjuvant
s i n c et h e ya r ew e l l - k n o w nt oi n d u c ei m m u n er e s p o n s e
[12,14] and examined their effects on VP1 subunit vacci-
nation. As a main immunogenic capsid protein of
FMDV, VP1 was successfully expressed and co-
expressed with two cytokines respectively in E.coli BL21
for the subsequent immunizations (Table 1). The result
of this study indicated that VP1 alone could induce
both humoral and cell-mediated immune response as
previously observed [8,9].
In our report, the adjuvant activity of GM-CSF and
IL-2 was analyzed. Compared with the VP1 group,
groups of GM-CSF/VP1, GM-CSF+VP1, IL-2/VP1 and
IL-2+VP1 could induce a much higher IgG level and
induce a significant T cell proliferation. It indicated that
GM-CSF and IL-2, as adjuvant, could induce both
humoral and cell-mediated immune response as for
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Figure 5 DTH of Guinea pig inoculated with different proteins. Fourteen days after the last inoculation, all Guinea pigs (N = 7) were
challenged counter-laterally with the 146 S antigen on right footpads as test and saline on left footpads as the negative control. The DTH was
defined as the thickness ratio of the right footpad to the left footpad at 24 h, 36 h and 48 h after the challenges.
Figure 6 Semi-quantitative RT-PCR of cytokine gene. The levels
of the Th1 or Th2 cytokines were quantitatively measured by semi-
quantitative RT-PCR and showed in Figure 6. For Th1 or Th2
cytokine, mRNA levels were the highest inoculated with the last
four groups, followed by co-inoculation with signal cytokine and
VP1, VP1 and VP1 + CFA group had the same level with former
groups. (1: control, 2: BoIL-2, 3: BoGM-CSF, 4: BoIL-2/VP1, 5: BoGM-
CSF/VP1, 6: VP1, 7: vaccine, 8: VP1+CFA, 9: IL-2+VP1, 10: GM-CSF
+VP1, 11: BoIL-2/GM-CSF/VP1, 12: BoIL-2/VP1+GM-CSF/VP1).
Zhang et al. Virology Journal 2011, 8:7
http://www.virologyj.com/content/8/1/7
Page 5 of 10CFA, suggesting that GM-CSF and IL-2 may become
the new potent adjuvant, which was consistent with pre-
viously documented [18-21]. Interestingly, the results of
ELISA and T cell proliferation showed that IL-2 and
GM-CSF, combined or mixed with VP1 as adjuvant,
induced a similar immune response level, which
indicated that IL-2 and GM-CSF co-expressed or co-
inoculated with VP1 did not impact their function as
adjuvant, which was inconsistent with the results by Shi
et al [9].
Cytokines interaction formed regulating network in
immune system. In this report, several approaches were
used to investigate the combined immune modulating
effects of IL-2 and GM-CSF as adjuvant on FMDV vac-
cination. All results showed that combined use of IL-2
and GM-CSF with VP1 had a better adjuvant effect than
single cytokine. It indicated there was synergistic effect
between IL-2 and GM-CSF, which was consistent with
the previous reports [15,22,23] This may be due to that
GM-CSF could attract APC and enhanced the antigen
presentation when the VP1 was injected with IL-2 and
GM-CSF [24]; IL-2 receptor expression was elevated for
the interaction between TCR and antigen [25]. Further-
more, IL-2 could directly enhanced IL-2 receptor
expression on antigen selected T cells [26] and could
further stimulate the growth and differentiation of those
T cells. Interestingly, the adjuvant effect was observed in
the BoIL-2/BoGM-CSF/VP1 group rather than in the
BoIL-2/VP1+BoGM-CSF/VP1 group, suggesting that
IL-2 and GM-CSF co-expressed as adjuvant had a better
synergistic effect than co-inoculated with VP1. This
probably because, in addition to the suggested synergies,
the two fusion cytokines may also had “bridge” function,
which could combine surface receptors of T cells,
macrophages and DC cell respectively, then formed IL-
2/GM-CSF “bridge” in T cells, macrophages and DC
cell. This “bridge” could increase the contact of DC and
T cell in a short time and the binding of receptor and
ligand, therefore, enhancing the antigen-presenting abil-
ity of APC, subsequently enhancing the level of cell and
humoral immune response, leading to a better adjuvant
function than single cytokine. Further experiments are
needed to test our hypothetic explanation.
DTH reflected the cell-mediated immune function and
especially the manifestation of Th1 type of effect cells.
Figure 7 Cytokine gene relative expression analysis of Semi-quantitative RT-PCR. Density of electrophoretic bands in Figure 6 were
analysed by band leader 3.0. Taking the data of HPRT bands as the background, Th1 and Th2 cytokine relative expression were evaluated by
comparing the intensities of their PCR products and showed in Figure 7. For Th1 or Th2 cytokine, mRNA levels were the highest inoculated with
the last four groups, followed by co-inoculation with signal cytokine and VP1, VP1 and VP1 + CFA group had the same level with former groups.
(1: control, 2: BoIL-2, 3: BoGM-CSF, 4: BoIL-2/VP1, 5: BoGM-CSF/VP1, 6: VP1, 7: vaccine, 8: VP1+CFA, 9: IL-2+VP1, 10: GM-CSF+VP1, 11: BoIL-2/GM-
CSF/VP1, 12: BoIL-2/VP1+GM-CSF/VP1).
Table 1 Experiment of groups with different treatment in
guinea pigs
Groups Treatments
Control PBS
1 BoIL-2
2 BoGM-CSF
3 VP1
4 inactivated FMDV vaccine
5V P 1emulsed in the complete fraued’s adjuvant (CFA) (VP1+
CFA)
6 Mixture of VP1and BoIL-2 (VP1+ BoIL-2)
7 Mixture of VP1 and BoGM-CSF (VP1+ BoGM-CSF)
8 Co-expressed product of BoGM-CSF/VP1
9 Co-expressed product of BoIL-2/VP1
10 Co-expressed product of BoIL-2/BoGM-CSF/VP1
11 Mixture of BoIL-2/VP1and BoGM-CSF/VP1 (BoIL-2/VP1+BoGM-
CSF/VP1)
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of ELISA and T cell proliferation. It was worth noting
that the DTH response level of VP1+CFA group was
higher than groups of single cytokine co-expressed or
mixed with VP1. The reason for this could be nonspeci-
fic stimulation of CFA.
In semi-quantitative RT-PCR, the mRNA levels for
IFN-g, IL-2, IL-4 and IL-10 were measured to assess the
profile of cytokines after immunization. Th1 and Th2
type cytokines were all increased after the co-inoculation
with recombined proteins in this study, which indicated
IL-2 and GM-CSF up-regulated, sequentially, both Th1
and Th2 responses. Groups of BoIL-2/BoGM-CSF/VP1
and BoIL-2/VP1+BoGM-CSF/VP1 could induce the
highest expression level of either Th1 or Th2 type cyto-
kines, followed by other groups, which were consistent
with the results of ELISA, T lymphocyte proliferation
response and DTH. CFA, as the most widely used adju-
vant in practical vaccination at present, induced a Th2
subset, which was also reported in other studies [27].
In this report we investigated the ability of IL-2 and
GM-CSF as adjuvant to modulate host immune
response against FMDV in the controlled experimental
conditions. IL-2 or GM-CSF could stimulate cellular
and humoral immune response, was a potential adjuvant
for the FMDV vaccination. We, for the first time,
showed that IL-2 or GM-CSF co-expressed or co-inocu-
lated with VP1 had the equal effect as adjuvant; Two
cytokines, GM-CSF and IL-2, when co-expressed with
VP1 had a better synergistic effect than that of the co-
inoculated. Further evaluation on efficacies and optimiz-
ing the immunization pigs and cattle will be the next in
our study.
Conclusions
In summary, the current study indicated the potential
for the use of IL-2 and GM-CSF as alternative adjuvant
for FMDV vaccination. The study also showed that
there was synergistic effect when GM-CSF and IL-2 co-
expressed with VP1, which will be useful for further
research on FMD vaccines.
Materials and methods
Reagents and antigens
RNA isolation and reverse transcription reagent Kits
were purchased from Promega (Madison, Wisc., USA),
ExTag DNA polymerase and all restriction enzymes
were purchased from TaKaRa (Dalian, China), BL21
expression vector, pGEX-6p-1, was purchased from Invi-
trogene, horseradish peroxidase(HRP)-conjugated goat
anti-mouse IgG, MTT and TMB were from Sigma
(St. Louis, USA). Eight-week-old female guinea pigs
were purchased from the Institute of Genetics of
Chinese Academy of Sciences.
FMDV O-serotype inactivated vaccine in oil emulsion
was acquired from Zhongmu Ltd. (Beijing, China), and
the 146 S antigen component was obtained from the pur-
ified as described previously and stored at 4°C. The con-
centration of the 146 s antigen was determined by the
Bradford protocol as described previously [28]. 146 S par-
ticle contains four major discrete proteins, VP1, VP2,
VP3 and VP4. VP1 is the dominant one and provides the
major neutralising and T cell epitopes among these four
proteins. Therefore, 146 S provides complete antigens/
epitopes for the ELISA and T cell proliferation assays.
Cloning, expression and co-expression of targeted genes
After isolation of peripheral blood mononuclear cells
(PBMC) from Holstein cow and stimulated with Con A
(10 μg/mg) for 2 h in vitro, total RNA was extracted
and reverse transcribed into cDNA by using RNA isola-
tion kit and reverse transcription reagent kit(Promega
Inc.) according to the manufacturer’s instructions.
The VP1 fragment was amplified from the plasmid
PMD18-VP1 (gift from Jin Huali, China Agricultural
University). The active mature peptide of BoIL-2 and
BoGM-CSF were amplified from cDNA. PCR conditions
and primers were indicated as Table 2. The PCR pro-
ducts of BoIL-2, BoGM-CSF and VP1 were purified and
digested. All the digested fragments were inserted into
the pGEX-6p-1 plasmid respectively, designated as
pGEX/BoIL-2, pGEX/GM-CSF and pGEX/VP1.
For the co-expression of BoIL-2 and VP1 in E. coli,
the VP1 fragment was amplified from the plasmid
PMD18-VP1 with the upstream primer VP1 F1 and
downstream primer VP1 R1 and digested with EcoRI
and XhoI. The IL-2 fragment was subcloned from plas-
mids pGEX/BoIL-2 and digested with BamHI and
EcoRI. The expression vector pGEX-6p-1 was also
digested with BamHI and XhoI. All the digested frag-
ments were ligated by T4 DNA ligase to yield three con-
structs, designated as pGEX/BoIL-2/VP1. Between
fragments of BoIL-2 and VP1, they were divided by five
glycine residues as linker.
For the co-expression of VP1 and BoIL-2, BoGM-CSF
in E. coli, IL-2, GM-CSF and VP1 were subcloned from
plasmids pGEX/BoIL-2, pGEX/GM-CSF and pGEX/
VP1. The PCR products of BoIL-2, BoGM-CSF and VP1
were purified and digested respectively. The expression
vector pGEX-6p-1 was also digested with BamHI and
XhoI. All the digested fragments were ligated by T4
DNA ligase respectively, designated as pGEX/IL-2/VP1,
pGEX/GM-CSF/VP1, pGEX/BoIL-2/BoGM-CSF/VP1.
Between fragments of BoIL-2 and VP1, BoIL-2 and
BoGM-CSF, or BoGM-CSF and VP1, they were joined
by five glycine residues as linkers.
These constructs were transformed into E. coli BL21
in LB plate with 50 μg/ml of Amp+ selection, followed
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enzyme digestions and PCR. The further confirmation
was performed by sequencing analysis.
The confirmed colonies were cultured into LB liquid
medium with 50 μg/ml of Amp+ at 37°C until the
OD600 value reached 0.5. The expression was induced
for 6 h with addition of IPTG to achieve a final concen-
tration of 1 mM.
Characterizations of expressed proteins by SDS-PAGE and
Western blot analysis
Sample of 100 μl cultures from each recombinant E. coli
were homogenized by ultrasonic treatment at 0°C. The
protein samples in supernatant and precipitation were
subjected in a 15% SDS-PAGE.
The inclusion bodies after ultrasonic treatment were
washed three times in 10 mmol/L Tris-Cl buffer
(10 mmol/L EDTA, 0.5% Tritonx-100, 0.2 mol/L Urea
pH = 8.0)and subsequently washed three times in 10
mmol/L Tris-Cl buffer (10 mmol/L EDTA, 0.5% Tri-
tonx-100, pH = 8.0).Then the inclusion bodies were
stepwise dialysed 6 h with Tris-Cl buffer(8 mol/L Urea,
6 mol/L Urea, 4 mol/L Urea and 2 mol/L Urea in each
Tris-Cl buffer) and PBS. Purified proteins were collected
for Western blot analysis and subsequent immunization.
Purified protein samples were transferred onto the
nitrocellulose membrane. The membrane was incubated
overnight in 5% bovine serum albumin in Tris-buffered
saline-Tween 20 at 4°C before washing for three times
in TBS. Subsequently, the membrane was incubated at
37°C for 2 h with the sera of guinea pig anti- BoIL-2,
guinea pig anti-BoGM-CSF and bovine FMDV positive
sera, diluted 1:1000 in blocking solution. The membrane
was washed in TBS and then incubated at 37°C for 2 h
with HRP-labeled goat anti-mouse IgG(Sigma), diluted
1:500 in blocking solution. The membrane was washed
again and the signals were developed with DAB
substrate.
Immunization and detection of FMDV antibody
Eighty four female guinea pigs were randomly divided
into twelve groups (N = 7 per group) as Table 1 and were
2-weeks old at the time of the first immunization. Protein
products were injected at the equal total dosage (500 μg
per guinea pig, in PBS) by hypodermic multisite injec-
tions respectively. Negative control group was injected
PBS (100 μl per guinea pig) with the same volume. All
test groups were immunized three times with two weeks
interval. Sera were collected before vaccination and on
the 14
th day post each immunization and subsequently
analyzed for detection of FMDV antibody.
ELISA plates were used to detect anti-FMDV antibo-
dies in guinea pigs as described previously [8,18]. 146 S
antigens (2 μg / m l )w e r ec o a t e do nE L I S Ap l a t e sa t4 ° C
overnight and subsequently reacted with sera diluted at
1:100 for 1 h at 37°C. Then sera reacted with 1:1000
diluted goat anti-guinea pigs IgG conjugated with HRP.
To detect the ELISA result, colorimetric reaction was
developed with TMB (Sigma) and stopped by H2SO4
and the OD reading was determined at 450 nm/655 nm
with a plate reader (Bio-Rad, CA, USA).
T lymohocyte proliferation
Guinea pigs were immunized as described earlier. Two
weeks after final immunization, Guinea pigs were sacri-
ficed and spleens were removed aseptically. Spleen cells
were plated at 5 × 10
4 cells per well and cultured in tri-
plicate wells for 48 h in presence of 10 μg/ml of 146 s
antigen or alone. Culture supernatants were tested to
quantify the T cell proliferation as described previously
Table 2 Primers for cloning PCR
Target genes* Primer code Primers Sequences (5’-3’)** Fragment length PCR condition
BoIL-2 BoIL-2 F 5’ GAA GGA TCC CAC CTC CTA CTT CAA
GCT CTA CG 3’
405 bp 94°C for 60 s, 62°C for 60 s and 72°C for
60 s, 35 cycles
BoIL-2 R 5’ CTA GAA TTC CAA GTC ATT GTT GAG
TAG ATG C 3’
BoGM-CSF BoGM-CSF F 5’ CTA GAA TTC GCA CCT ACT CGC CCA
CCC AA 3’
378 bp 94°C for 60 s, 62°C for 60 s and 72°C for
60 s, 35 cycles
BoGM-CSF R 5’ TTA CCG CGG CTT CTG GGC TGG TTC
CCA G 3’
VP1 VP1 F 5’GCA CCG CGG ACC ACC TCT GCG GGT
GAG TCT 3’
669 bp 94°C for 60 s, 61°C for 60 s and 72°C for
60 s, 35 cycles
VP1 R 5’GAC CTC GAG CAG AAG CTG TTT TGC
GGG T 3’
VP1 F1 5’GCA GAA TTC ACC ACC TCT GCG GGT
GAG TCT 3’
VP1 R1 5’GAC CTC GAG CAG AAG CTG TTT TGC
GGG T 3’
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stimulation index (SI), which is the ratio of OD570 nm of
stimulated well (stimulated cell) to OD570 nm of unsti-
mulated one [18].
Antigen specific delayed-type Hypersensitivity (DTH)
Two weeks after the last immunization, Guinea pigs
were injected with the 146 S antigen into the right foot-
pads and saline into the left as the negative control.
Then the thicknesses of footpads were measured respec-
tively at 24 h, 48 h and 72 h with micrometer to assess
the effects of DTH [8,18].
Semi-quantitative RT-PCR for mRNA of cytokines
Guinea pigs were immunized as described earlier. Two
weeks after final immunization, Guinea pigs were sacri-
ficed and spleens were removed aseptically. The lympho-
cytes were separated from spleens and plated in the 6-well
microtiter plate at 5 × 10
4 cells per well. The lymphocytes
were cultured in triplicate wells with antigen stimulations
for 1 h in RPMI-1640 containing 10% FCS. The total RNA
was extracted from those cells and the cDNA was synthe-
sized as described above. PCR conditions were optimized
with specific primers for the housekeeping gene (HPRT)
or cytokine genes indicated as Table 3.
PCR parameters were performed with minor modifica-
tions. Briefly, the PCR mixtures contained 5 μlo fP C R
buffers, 4 μl of dNTP, 0.5 μlo fE x T a qp o l y m e r a s e ,2μg
of cDNAs and 0.5 μl of each primer. The PCR was per-
formed for 32 cycles with parameters of denaturation at
94°C for 1 min, annealing at 60°C for 30 s, extension at
72°C for 1 min, and a final extension at 72°C for 10
min. cDNA from each group was first normalized with
the house-keeping gene, HPRT as a reference, each
adjusted cDNA was used as template to amplify IFN-g,
IL-2, and IL-4, respectively, according to the conditions
described above. All these PCR products were subjected
onto electrophoresis on 1.5% of agarose gel and photo-
graphed under the UV light [18]. Density of electro-
phoretic bands in agarose gel were analysed by band
leader 3.0. Taking the data of HPRT bands as the back-
ground, the relative amount of mRNAs for the cytokine-
specific genes was evaluated by comparing the intensi-
ties of their PCR products.
Statistical analysis
Statistical significance between the treatment groups was
calculated using One-sided Student’s t-test and P < 0.05
was considered statistically significant.
Acknowledgements
This work was supported by the National High Technology Research and
Development Program (No. 2001AA249032) and the National “10.5” Key
Technologies R&D Program (No. 2002BA514A-16-4).
Author details
1College of Veterinary Medicine, China Agricultural University, Beijing 100193,
China.
2State Key Lab of Agro-Biotechnology and College of Biological
Sciences, China Agricultural University, Beijing 100193, China.
3College of
Veterinary Science, Qingdao Agricultural University, Qingdao 266109, China.
Authors’ contributions
CZ carried out the experiments and wrote the manuscript. BW participated
in experimental design and paper revise. MW conceived the studies and
participated in experimental design and coordination. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 August 2010 Accepted: 9 January 2011
Published: 9 January 2011
References
1. Audibert FM, Lise LD: Adjuvants: current status, clinical perspectives and
future prospects. Immunology Today 1993, 14:281-284.
2. Vogel FR: Adjuvants in perspective. Dev Biol Stand 1998, 92:241-248.
3. Gupta RK, Rost BE, Relyveld E, Siber GR: Adjuvant properties of aluminium
and calcium compounds. Pharm Biotechnol 1995, 6:229-248.
4. Gupta RK: Aluminum compounds as vaccine adjuvants. Adv Drug Deliv
Rev 1998, 32(3):155-1725.
5. el Kassas H, Kirkwood JM: Adjuvant application of interferons. Semin Oncol
1996, 23(6):737-743.
6. Singh M, O’Hagan D: Advances in vaccine adjuvant. Nat Biltechnol 1999,
17(11):1075-1081.
7. Scheerlinck JY: Genetic adjuvants for DNA vaccines. Vaccine 2001,
19:2647-2656.
8. Shi XJ, Wang B, Zhang C, Han CL, Wang M: Expressions of Bovine IFN-γ
and Foot-and-Mouth Disease VP1 antigen in P. pastoris and their
effects on mouse immune response to FMD antigens. Vaccine 2006,
24(1):82-89.
9. Shi XJ, Wang B, Wang M: Immune enhancing effects of recombinant
bovine IL-18 on foot-and-mouth disease vaccination in mice model.
Vaccine 2007, 25:1257-1264.
10. Wang X, Zhang XY, Kang YM, Jin HL, Du XG, Zhao G, Yu Y, Li JY, Su BW,
Huang C, Wang B: Interleukin-15 enhance DNA vaccine elicited mucosal
and systemic immunity against foot and mouth disease virus. Vaccine
2008, 26(40):5135-5144.
Table 3 Primers for Semi-quantitative RT-PCR
Target
genes
primers Fragment
length
References
HPRT 5’ GTT GGA TAC AGG CCA GAC
TTT GTT G
3 GAG GGT AGG CTG GCC TAT
GGC T
352 bp [28]
IL-2 5’ TCC ACT TGA AGC TCT
ACA G
3’ GAG TGA AAT CCA GAA
CAT GCC
247 bp
IFN-g 5’ CAT TGA AAG CCT AGA
AAG TCT G
3’ CTC ATG GAA ATG CAT CCT
TTT TCG
267 bp
IL-4 5’ GAA AGA GAC CTT GAC ACA
GCT G
3’ GAA CTC TTG CAG GTA ATC
CAG G
240 bp
IL-10 5’ CCA GTT TTA CCT GGT AGA
AGT GAT G
3’ TCT GGT CCT GGA GTC CAG
CAG ACT CAA
324 bp
Zhang et al. Virology Journal 2011, 8:7
http://www.virologyj.com/content/8/1/7
Page 9 of 1011. Su B, Wang J, Wang X, Jin H, Zhao G, Ding Z, Kang Y, Wang B: The effects
of IL-6 and TNF-alpha as molecular adjuvants on immune responses to
FMDV and maturation of dendritic cells by DNA vaccination. Vaccine
2008, 26(40):5111-5122.
12. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C,
Schow P, Ross ME, Klumpp TR, Soiffer RJ: Selective modulation of human
natural killer cell in vivo after prolonged infusion of low-dose
recombinant interleukin-2. J Clin Invest 1993, 91(1):123-132.
13. Romagnani S: Th1/Th2 cells. Inflamm Bowel Dis 1999, 5(4):285-294.
14. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S,
Cheever MA: Granulocyte-macrophage colony-stimulating factor: An
effective adjuvant for protein and peptide-based vaccines. Blood 1996,
88(1):202-210.
15. Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson RM, Berzofsky JA,
Khleif SN: The combination of GM-CSF and IL-2 as local adjuvant shows
synergy in enhancing peptide vaccines and provides long term tumor
protection. Vaccine 2007, 25(31):5882-91.
16. Yoon HA, Aleyas AG, George JA, Park SO, Han YW, Lee JH, Cho JG, Eo SK:
Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine
against pseudorabies virus through enhanced immune responses.
Microbiol Immunol 2006, 50(2):83-92.
17. Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW: Co-expression of
granulocyte-macrophage colony-stimulating factor with antigen
enhances humoral and tumor immunity after DNA vaccination. Vaccine
2002, 20(9-10):1466-1474.
18. Sin JI, Kim JJ, Ugen KE, Ciccarelli RB, Higgins TJ, Weiner DB: Enhancement
of protective humoral (Th2)and cell-medicated (Th1) immune responses
against herpes simplex virus-2 through co-delivery of granulocyte-
macrophage colony-stimulating factor expression cassettes. Eur J
Immunol 1998, 28:3530-3540.
19. Hartung T, von Aulock S, Freitag M, Höxtermann S, Stücker M, Hoffmann K,
Altmeyer P, Kottke A, Wendel A: Blood cytokine response of low-dose
molgramostim(rhGM-CSF) -treated patients. Cytokine 2000, 12:1570.
20. Ogawa T, Kusumoto M, Kuroki S, Nagata S, Yamanaka N, Kawano R,
Yoshida J, Shinohara M, Matsuo K: Adjuvant GM-CSF cytokine gene
therapy for bresat cancer. Gan To Kagaku Ryoho 2001, 28(11):1512-1514.
21. Somasundaram C, Takamatsu H, Andréoni C, Audonnet JC, Fischer L,
Lefèvre F, Charley B: Enhanced protective response and immunoadjuvant
effects of procine GM-CSF on DNA vsccination of pigs against Aujeszky’s
disease virus. Vet Immunol Immunopathol 1999, 70(3-4):277-287.
22. Boyaka PN, McGhee JR: Cytokines as adjuvants for the induction of
mucosal immunity. Adv Drug Deliv Rev 2001, 51:71-19.
23. Westermann J, Reich G, Kopp J, Haus U, Dörken B, Pezzutto A:
Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2
plus interferon alpha in the treatment of metastatic renal cell
carcinoma: a pilot study. Cancer Immunol Immunother 2001,
49(11):613-620.
24. Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA: Mechanisms of cytokine
synergy essential for vaccine protection against viral challenge. Int
Immunol 2001, 13(7):897-908.
25. Cantrell DA, Smith KA: Transient expression of interleukin 2 receptors.
Consequences for T cell growth. J Exp Med 1983, 158(6):1895-1911.
26. Depper JM, Leonard WJ, Drogula C, Kronke M, Waldmann TA, Greene WC:
Interleukin 2(IL-2) augments transcription of the IL-2 receptor gene. Proc
Natl Acad Scin USA 1985, 82(12):4230-4234.
27. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J: In
interleukin-4-deficient mice, alum not only generates T helper 1
responses equivalent to freund’s complete adjuvant, but continues to
induce T helper 2 cytokine production. Eur J Immunol 1996,
26(9):2062-2066.
28. Jin HL, Li YJ, Ma ZH, Zhang FC, Xie QG, Gu DF, Wang B: Effect of chemical
adjuvants on DNA vaccination. Vaccine 2004, 29(21~22):2925~2935.
doi:10.1186/1743-422X-8-7
Cite this article as: Zhang et al.: GM-CSF and IL-2 as adjuvant enhance
the immune effect of protein vaccine against foot-and-mouth disease.
Virology Journal 2011 8:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. Virology Journal 2011, 8:7
http://www.virologyj.com/content/8/1/7
Page 10 of 10